title: 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass.
abstract: 1-deamino-8-D-Arginine vasopressin (DDAVP) shortens the bleeding time in some patients with platelet dysfunction and decreases blood loss in some cardiopulmonary bypass patients. We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP. Platelets from 8 cardiopulmonary bypass patients, receiving DDAVP immediately after surgery, were compared to those of 14 patients not receiving DDAVP. We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP. Fixed platelets, stained with monoclonal fluorescein (FITC)-labeled antibodies directed against GPIb (CD42b antigen), GPIb/IX, GPIIb/IIIa (CD41a antigen), CD63 antigen (a platelet activation protein), and P-selectin (CD62 antigen) were studied by flow cytometry. Binding of CD42b monoclonal antibody (MoAb) and anti-GPIb/IX to platelets from both groups of bypass patients increased during the 18-20 hr after surgery, but the group receiving DDAVP showed the greater increase (P = 0.032). Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time. No changes were seen in binding of other antibodies. When platelets from normal donors were incubated with DDAVP for 20 hr, there were increases in platelet surface CD42b MoAb binding, while immunogold-stained transmission electron micrographs of permeabilized platelets demonstrated decreases in cytoplasmic CD42b MoAb binding. DDAVP increases platelet membrane GPIb expression in a variety of patients and may account for improvement in hemostasis seen in some studies. Redistribution of GPIb from the cytoplasm to the membrane may account for this increased expression.
authors.affiliation: Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: E M
authors.initials: EM
authors.lastname: Sloand
authors.forename: D
authors.initials: D
authors.lastname: Alyono
authors.forename: H G
authors.initials: HG
authors.lastname: Klein
authors.forename: P
authors.initials: P
authors.lastname: Chang
authors.forename: M
authors.initials: M
authors.lastname: Yu
authors.forename: F G
authors.initials: FG
authors.lastname: Lightfoot
authors.forename: C
authors.initials: C
authors.lastname: Kessler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001791:Blood Platelet Disorders / Q000097:blood*; D001792:Blood Platelets / Q000187:drug effects; D002315:Cardiopulmonary Bypass; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects / Q000502:physiology*; D014842:von Willebrand Diseases / Q000097:blood*
chemical_list: D010980:Platelet Membrane Glycoproteins; D003894:Deamino Arginine Vasopressin